



## Schedule At a Glance for the AHNS 2025 Meeting at COSM *Mind, Machine, and Medicine: Mobilizing Behavioral Health, AI, and Education to Advance Head & Neck Care*

Additional information available at <https://cosm.md/>

### AHNS Accreditation Statement for AHNS 2025

The American Head & Neck Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Head & Neck Society designates this live activity for a maximum of 14.25 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### ABOHNS Continuous Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery's Continuing Certification program (formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

### ABS Continuous Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Program Chair: Susan McCammon, MD

Program Co-Chairs Aru Panwar, MD, FACS, Andrew Shuman, MD

## AGENDA:

*\*\*More Information to be Announced. Tentative Schedule – Subject to Change*

### Tuesday, May 13, 2025 (Pre-Meeting Courses)

Time	Title	Location
7:30am - 12:00pm	<b>The AHNS Head &amp; Neck Surgery Symposium for Residents &amp; Fellows (non-CME)</b> Course Co-Directors: Kelly Malloy, MD, and Ben Judson, MD, MBA	<b>Bolden 6</b>
This half-day symposium presents several informative lectures on head and neck surgical procedures and treatments, presented by leading head and neck surgeons.		
7:30am - 12:00pm	<b>Thyroid, Parathyroid, and Neck Ultrasound Course Didactic Session</b> Course Co-Directors: Russell Smith, MD, and Lisa Orloff, MD, FACS, FACE	<b>Strand 10</b>
The objective of this course is to introduce the practicing surgeon to office-based ultrasound examination of the thyroid and parathyroid glands and related pathology. The distinction of normal from malignant lymphadenopathy is emphasized with a demonstration of the comprehensive examination of lymph node basins in cervical zones I-VI. The process of ultrasound guided FNA of thyroid nodules and enlarged lymph nodes is demonstrated in didactic lecture format. In addition, skill sessions allow the surgeon to learn varied techniques of FNA of lesions in phantom models.		
8:30am - 5:05pm	<b>2025 AHNS Innovation and Entrepreneurial Symposium (non-CME)</b> Course Director: Jose P. Zevallos, MD, MPH Course Co-Director: Baran Sumer, MD	<b>Strand 13B</b>
The symposium will be an introductory, all-day course designed for surgeons and academic physicians. It offers insights into entrepreneurship, covering key aspects such as intellectual property protection, capital raising, balancing clinical responsibilities, navigating technology transfer offices, patenting, commercialization, manufacturing, regulatory compliance, and conflict of interest management.		

Time	Title	Location
<b>12:00pm - 4:30pm</b>	<b>Thyroid, Parathyroid, and Neck Ultrasound Course Hands-on Session</b> Course Co-Directors: <i>Russell Smith, MD, and Lisa Orloff, MD, FACS, FACE</i>	<b>Strand 10</b>
<p>The use of patient volunteers with thyroid and parathyroid pathology and lymphadenopathy will allow supervised hands-on experience with transverse and longitudinal ultrasound methods. Participants will be instructed in the practical details and hurdles in developing office-based ultrasound.</p>		
<b>1:00pm - 5:00pm</b>	<b>Head &amp; Neck Microvascular Reconstructive (non-CME)</b> Course Director: <i>Jamie Ku, MD, BS, and Course Co-Director: Steven Chinn, MD, MPH, BS</i>	<b>Bolden 6</b>
<p>In this workshop, a group of experts will provide insights and pearls of wisdom as they provide a variety of defect-oriented solutions to some of the most challenging head and neck reconstructive defects. In the second part of the workshop, the expert panelists will face each other off in mini debates on the latest controversial topics in head and neck reconstruction. This workshop is designed to be interactive with opportunities to participate and ask questions.</p>		
<b>5:30pm - 6:30pm</b>	<b>Young Members Service Chairs Reception</b>	<b>TBD</b>
<b>6:00pm - 7:30pm</b>	<b>Drawn to Uncertainty: An Interactive Workshop for Medical Educators (non-CME)</b> Course Director: Mark Gilbert, PhD	<b>Foster 1</b>
<p>For medical and especially surgical teaching careful observation, tolerance to uncertainty and the need for empathy either side of the healthcare interaction is critical. The visual arts are increasingly recognized as providing powerful resources to effectively address competencies related to a more patient-centered, empathic, and holistic approach to care.</p> <p>This interactive workshop draws upon the role the artistic medium of portraiture to develop emotional responses, provide alternative forms of representation, and promote dialogue in ways that parallel the relational and diagnostic challenges experienced in clinical interactions.</p> <p>The workshop will be facilitated by Dr. Mark Gilbert who has worked on a number of high-profile art projects, illuminating patient and caregiver experience of illness. The resulting collections were exhibited in venues around the world, including the National Portrait Gallery, London.</p>		

Wednesday, May 14, 2025

Time	Title	Location
7:00am - 5:00pm	Centurion Lounge	Foster 1
7:00am - 8:00am	New Member Induction and Research Awards Ceremony	Celestin D
8:00am - 8:15am	Welcome and Introduction	Celestin D
8:15am - 9:00am	Presidential Address and Presidential Awards <i>William Lydiatt, MD</i>	
9:00am - 9:05am	Introduction	
9:05am - 9:45am	Distinguished Keynote Lecture <b>Mind, Machine-And You: The Psychology of Sustainable Success</b> Keynote Speaker: <i>Brett Haskell, PhD, LP, CMPC</i>	
9:45am-10:15am Break with Exhibitors		

10:15am - 11:15am	John Conley Lecture <b>Impacting the Mental Health Crisis as Non-psychiatric Specialists</b> Keynote Speaker: <i>David Rubin, MD</i>	Celestin D
-------------------	--	------------

Time	Title	Location	Time	Title	Location
11:15am - 12:00pm	Celestin D <b>Scientific Session 1: HPV-positive Oropharyngeal Disease</b> Moderators: <i>Sidharth Puram, MD, PhD and Eleni Rettig, MD</i>		11:15am - 12:00pm	Celestin E <b>Panel 1: Endocrine Surgery: Emerging and Evolving Technologies</b> Moderator: <i>Allen Ho, MD</i> Faculty: <i>Victoria Banuchi Crespo, MD, MPH, BA, Diana Kirke, MBBS, MPhil, and David Shonka, MD</i>	
<b>Expert Introduction:</b> <i>Sidharth Puram, MD, PhD</i> 1. HPV+ OPSCC recurrence risk after TORS is associated with a smaller fraction of tumor cells containing detectable E6/E7 RNA – <i>Jean-Nicolas Gallant, MD, PhD</i> 2. The Performance of Tumor Tissue Modified Viral-Human Papillomavirus, An Institutional Update – <i>Peter Cook</i> 3. Neoadjuvant chemotherapy and transoral robotic surgery as definitive treatment in p16+ve oropharyngeal cancer: Outcomes of NECTORS trial – <i>Nadar Sadeghi</i> 4. Circulating tumor HPV-DNA and Chemotherapy Response in HPV-Associated Oropharyngeal Cancer – <i>Augustin G. Vannier</i> 5. Postoperative Circulating Tumor HPV DNA Kinetics in Surgically Managed Patients with HPV(+)OPSCC – <i>Cecelia M. Hidalgo, BA</i>			We will review emerging tools in parathyroid and thyroid surgery with illustrative case examples. Controversies regarding practical value and utility of these tools will be emphasized.  At the conclusion of this session, participants will be able to: <ul style="list-style-type: none"><li>• Demonstrate key indications and contraindications for radiofrequency ablation and other ablation technologies.</li><li>• Articulate new approaches to nerve monitoring to protect against nerve paralysis.</li><li>• Evaluate the key uses for parathyroid autofluorescence in thyroid and parathyroid surgery.</li></ul> 11:15 am Introduction – <i>Allen Ho, MD</i> 11:17 am Ablation Technologies – <i>Victoria B. Crespo, MD, MPH, BA</i> 11:27 am Nerve Monitoring Advances – <i>Diana Kirke, MBBS, MPhil</i> 11:37 am Parathyroid Autofluorescence – <i>David Shonka, MD</i> 11:47 am Case Discussion		

12:00pm-1:00pm Lunch with Exhibitors
--------------------------------------

**1:00pm - 2:00pm** **Celestin D**  
**Patient Care Controversies: ctDNA Ready for Primetime?**  
 Moderator: *Eleni Rettig, MD*  
 Faculty: *Chris Holsinger, MD, Eleni Rettig, MD, Scott Roof, MD, BS and Melinda Windon, MD*

This panel will explore emerging applications and controversies surrounding the use of circulating tumor DNA (ctDNA) in head and neck cancer, with discussions on its role in underserved populations, HPV-positive and negative cancers, and ongoing clinical trials. The session will feature presentations by published experts in the field, followed by a debate addressing key questions about ctDNA's readiness for clinical implementation and its potential to guide post-operative treatment strategies.

At the conclusion of this session, participants will be able to:

- Describe the role for use of ctDNA in surveillance for HPV-mediated SCC of the oropharynx.
- Better understand the role of ctDNA for patients with HPV-negative SCC of the head and neck.
- Discuss the role of ctDNA as a non-invasive tool for early diagnosis, surveillance, and assessing response to treatment.

1:00 pm Introduction – *Eleni Rettig, MD*  
 1:03 pm The Role of ctDNA in Underserved Populations – *Melinda Wonton, MD*  
 1:11 pm Use of ctHPV DNA as a Tool for Clinical Monitoring and Long-term Cancer Surveillance – *Scott Roof, MD, BS*  
 1:19 pm The Role of ctDNA and its Relevance in HPV-negative Cancers – *Eleni Rettig, MD*  
 1:27 pm The Role of ctDNA in Ongoing Clinical Trials and Future Roles in Post-op Adjuvant Therapy – *Chris Holsinger, MD*  
 1:35 pm Controversies (Discussion and Debate)

**1:00pm - 2:00pm** **Celestin E**  
**Panel 2: Horror Stories in Head and Neck Reconstruction: Is It a Thing of the Past?**  
 Moderators: *Alice Lin, MD and Elizabeth Anne Nicolli, MD*  
 Faculty: *Alexandra Kejner, MD, Brett Miles, DDS, MD, and Mark Wax, MD*

We will start with a case management format for a few strategies that can be used for "horror story" cases and follow with a short session on tips and tricks that the panelists have adopted over the years.

At the conclusion of this session, participants will be able to:

- Recognize several factors that can lead to failure of head and neck reconstruction.
- Manage stressful and complicated reconstructive situations using skills learned during this session.
- Plan to prevent many complications that can arise in head and neck reconstruction.

1:00 pm Introduction - *Alice Lin, MD*  
 1:05 pm Potions and Tinctures - Evidence Based Tricks - *Alexandra Kejner, MD*  
 1:25 pm When is It Time to Call It a Day, Use the Flap as a Biological Dressing and Come Back Another Day? - *Mark Wax, MD*  
 1:35 pm When You Do Everything Right, Accepting Failures Supporting Yourself and Your Patients - *Brett Miles, DDS, MD*  
 1:45 pm Q&A

**2:00pm - 2:45pm** **Celestin D**  
**Panel 3: Parotid Tumor Garden: When to Watch and When to Prune**  
 Moderator: *Alexandra Kejner, MD*  
 Faculty: *Heather Edwards, MD, William Ryan, MD, Jessica Maxwell, MD, MPH*

This panel addresses tumors of the parotid and when it is appropriate to observe/monitor them and when observation is not an option. We will go over imaging characteristics, diagnostic dilemmas, approach to patient counseling, and will go over specific cases with audience participation.

At the conclusion of this session, participants will be able to:

- Classify parotid tumors into those that can be observed and those which need immediate surgical attention.
- Identify solutions and strategies with difficult to diagnose tumors.
- Demonstrate appropriate and evidence-based counseling for patients who are surgery-averse and prepare a surveillance plan for these.

2:00 pm Introduction to Parotid Tumors – *Alexandra Kejner, MD*  
 2:05 pm Monsters of the Deep (Lobe) – *Jessica Maxwell, MD, MPH*  
 2:15 pm Lost in (Parapharyngeal) Space – *William Ryan, MD*  
 2:25 pm Handle with Care (Frailty and Parotid Surgery - Surveillance) – *Heather Edwards, MD*  
 2:35 pm Audience Poll/Panel Discussion

**2:00pm - 2:45pm** **Celestin E**  
**Scientific Session 2: Quality of Life & Health Behaviors**  
 Moderators: *Neerav Goyal, MD, MPH, Katherine Hutchenson, PhD*

**Expert Introduction:** *Neerav Goyal, MD, MPH*

1. Post-Diagnosis Smoking Cessation and Its Effect on Survival Outcomes in Head and Neck Cancer Patients: Findings from a Prospective Cohort Study – *Alham Mohebbi, MD*
2. Beyond aspiration: revisiting residue rates and MBS swallow profiles from the ECOG-ACRIN E3311 trial – *Beatrice Manduchi, PhD*
3. Efficacy of a Brief Cognitive Behavioral Therapy for Head and Neck Cancer Survivors Across Domains of Body Image Distress: Secondary Outcomes from the BRIGHT Pilot Randomized Clinical Trial – *Haley Hullfish, MD*
4. Variations in clinical presentation and physician decision-making between frail and not-frail head and neck cancer patients – *Eoin F. Cleere, MD*
5. Clinical and sociodemographic determinants of sustained head and neck cancer survivorship clinic attendance – *Maryanna S. Owoc, MD, PhD*

3:15pm - 4:00pm

Celestin D

**Scientific Session 3: Immunotherapy**

Moderators: *Mirabelle Sajvesi, MD, and Nyall London, MD, PhD*

**Expert Introduction:** *Nyall London, MD, PhD*

1. Five-year OS and DFS in HPV-associated HNSCC following neoadjuvant immunotherapy + GTV-only SBRT from the Providence NIRT-1 study – *Robert H. Hermann, MD*
2. Investigating the Role of Regulatory T Cells in Pathologic Response to Different Neoadjuvant Immune Checkpoint Inhibitor (ICI) Combinations in HNSCC – *Matthias Brand, MD*
3. A Phase 2, Open-Label Study of Intratumoral Vidutolimod in Combination With Intravenous Pembrolizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma – *Deborah J. Wong, MD*
4. Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: The MD Anderson Experience – *Shorook Naara, MD, PhD*
5. Validation of a Peripheral Blood Prognostic Signature for Overall Survival in Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors and Comparison to the Systemic Inflammatory Response Index (SIRI) – *Sina Dadafarin, MD*

3:15pm - 4:00pm

Celestin E

**Panel 4: More than Skin Deep – Reviewing ‘Resectability’ for Cutaneous Malignancies**

Moderator: *Karen Choi, MD*

Faculty: *Christopher Barker, MD, Steven Chinn MD, MPH, BS, Antoinette Esce, MD, and Cecilia Schmalbach, MD, MSc, FACS*

In a new era where there are now several new options that can offer potential cures for advanced cutaneous malignancies, there are changing perspectives on the role for surgical resection that requires an in-depth review of technical, medical, and ethical considerations for surgical limitations. Specific clinical challenges will be presented via clinical vignettes that pose common dilemmas that arise including technical limits of resection, alternative treatment strategies, and ethical considerations.

At the conclusion of this session, participants will be able to:

- Evaluate the evidence surrounding response-adapted surgery, the role of definitive radiation in unresectable skin cancers and compare the nuances in defining “resectability” from the perspective of surgeons and radiation oncologists.
- Appraise the role of immunotherapy in the management of high-risk cutaneous malignancies and articulate the challenges unique to the immunosuppressed population.
- Define affective forecasting and apply shared decision-making techniques to complex conversations about locally advanced cutaneous malignancies.

3:15 pm Where to Draw the Line: Resectability and Response Adapted Surgery – *Steven Chinn, MD, MPH, BS*

3:25 pm Staying In (and Straying From) My Lane: Unresectable Skin Cancer and Radiation Therapy – *Christopher Barker, MD*

3:35 pm Immunotherapy for High-risk Cutaneous Malignancies – *Cecelia Schmalbach, MD, MSc, FACS*

3:45 pm The Ethics of Resectability and Shared Decision Making – *Antoinette Esce, MD*

3:55 pm Q&A

4:00pm - 5:00pm

Celestin D

**Women’s Panel: The 7-year Itch - Exploring Leadership and Alternative Career Pathways to Academic Medicine**

Moderator: *Shirley Su, MBBS & Amy Anne Lassig, MD, BA, MS*

Faculty: *Beven Yueh, MD, Dennis Kraus, MD, FACS, Cherie Ann Nathan, MD, FACS, and Bert O’Malley, MD*

Mid-career is a time of change and needs careful planning. Many pathways exist outside of traditional academia. We present strategies from AHNS members who have made the leap and been successful in their alternative career pathways.

At the conclusion of this session, participants will be able to:

- Identify leadership opportunities outside of traditional academia.
- Understand the strategies for developing and fostering a strong and productive team.
- Discuss the pros and cons of career pathways including medical schools, hospital executive leadership and working with business.

4:00pm - 5:00pm

Celestin E

**Panel 5: 20 Years After Katrina: Reflections on Practicing Medicine with Limited Resources**

Moderator: *Andrew Shuman, MD*

Faculty: *Peter DeBlieux, MD, and Anna Pou, MD*

Hurricane Katrina led to devastation that tested clinicians in unprecedented ways. Two clinicians who experienced this disaster first-hand will reflect on how clinicians and institutions can respond to hurricanes, pandemics, and other unexpected resource constraints.

At the conclusion of this session, participants will be able to:

- Describe how natural disasters can create unprecedented constraints on the practice of medicine and surgery.
- Explain how institutional preparation and proactive policies can mitigate the burden of resource allocation on clinicians and patients.
- Apply principles of scarce resource allocation to varied challenges from natural disasters, to pandemics, to more mundane challenges such as limited OR time.

4:00 pm Introduction – <i>Shirley Su, MBBS</i> 4:03 pm How Do You Develop and Foster a Strong Productive Team Dynamic? – <i>Bevan Yueh, MD</i> 4:13 pm Charting a Path Through Executive Hospital Leadership – <i>Bert O'Malley, MD</i> 4:23 pm Medical School Leadership Pathways – <i>Bevan Yueh, MD</i> 4:33 pm Business Leadership and Working with Industry – <i>Dennis Kraus, MD, FACS</i> 4:43 pm Q&A	4:00 pm Ethical Principles of Scarce Resource Allocation – <i>Andrew Shuman, MD</i> 4:08 pm Caring for Patients in the Midst of Chaos – <i>Anna Pou, MD</i> 4:23 pm Transitioning From a Sprint to a Marathon – <i>Peter DeBlieux, MD</i> 4:38 pm Q&A
---	--

#AHNSWomen

5:00pm - 6:00pm

AHNS Business Meeting

Celestin D

6:00pm - 7:30pm

Women in H&N Service Reception

Bolden 6

2025 Margaret Butler Award for Outstanding Mentor of Women in Head and Neck Surgery

6:00pm - 6:45 pm

Celestin D

MCLA-158-CLo2 Clinical Trial Update (non-CME)

Presented by: *Alexa Boykin, PharmD, Senior Medical Science Liaison, Merus.*

MCLA-158-CLo2 is a phase 3, open-label, randomized, controlled, multicenter study comparing petosemtamab versus investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease, with a focus on patients who have progressed after anti-PD-1 therapy and platinum-containing therapy.

6:00pm - 7:30pm

Celestin E

NRG-HN006 Clinical Trial Update (non-CME)

Presented by: *Stephen Lai, MD, PhD*

Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Update.

6:45pm-7:30 pm

Celestin D

NRG-HN014 Clinical Trial Update (non-CME)

Presented by: *Neil Gross, MD, FACS*

NRG-HN014 is a clinical study testing if adding "Cemiplimab" (REGN2810) prior to surgery can extend the length of time without cancer recurrence for patients with advanced skin cancer.



Thursday, May 15, 2025

*\*\*More Information to be Announced. Tentative Schedule – Subject to Change*

Time	Title	Location
7:00am - 5:00pm	Centurion Lounge	Foster 1
7:00am - 8:00am	Fellowship Information Session	Celestin D
8:00am - 9:00am	Hayes Martin Lecture The Future of Artificial Intelligence in Medicine: The Example of Medical Imaging Keynote Speaker: Dr. Curtis Langlotz, MD, PhD	Celestin D

Time	Title	Location	Time	Title	Location
9:00am - 9:45am	Panel 6: Precision Surgery: The Future of Artificial Intelligence in Head and Neck Oncology Moderator: Andres Bur, MD Faculty: Janice Farlow, MD, PhD, Chris Holsinger, MD, and Melina Windon, MD  This panel will explore the transformative impact of artificial intelligence (AI) on head and neck oncology, focusing on its growing role in cancer care and addressing the associated ethical challenges. Discussions will emphasize advances in precision oncology and the potential of large language models (LLMs) to improve clinical efficiency, providing actionable insights for integrating AI into surgical practice.  At the conclusion of this session, participants will be able to: <ul style="list-style-type: none"><li>Assess the potential of artificial intelligence (AI)-based tools in precision medicine for head and neck cancer, focusing on their capabilities, applications, and limitations.</li><li>Identify and address key ethical considerations in integrating AI into clinical workflows, including mitigating bias, safeguarding data privacy, and ensuring transparency in decision-making.</li><li>Utilize advancements in large language models (LLMs) to enhance clinical efficiency by streamlining documentation, improving patient communication, and supporting evidence-based practice.</li></ul>	Celestin D	9:00am - 9:45am	Scientific Session 4: Cancer Biology Moderators: Carissa Thomas, MD, PhD, FACS, and Michael Topf, MD  <b>Expert Introduction:</b> Carissa Thomas, MD, PhD, FACS <ol style="list-style-type: none"><li>scRNA-seq and genomics analyses reveal key mechanisms of inverted papilloma-associated sinonasal squamous cell carcinoma malignant transformation – Tolani Olonisakin, MD, PhD</li><li>Establishing a Patient-Derived Xenograft Library for Head and Neck Cancer: Unveiling Mechanisms of Adaptive Chemotherapy Resistance – Chikako Yagi, MD</li><li>The Epigenetic link between Psychosocial Stress and Survival of Oral Squamous Cell Carcinoma – Traeden Wilson, MD</li><li>Intratumoral Chemokine Priming Enhances Immune Surveillance and Potentiates Checkpoint Inhibition in Head and Neck Cancer – Robert Saddawi-Konefka, MD</li><li>Epigenomic features and vulnerabilities of head and neck squamous cell carcinoma metastasis – Wesley L. Cai, MD, PhD</li></ol>	Celestin E
9:00 am	Introduction to Artificial Intelligence – Andres Bur, MD				
9:10 am	Diagnostic and Prognostic Tools in Head and Neck Oncology – Christopher Holsinger, MD				
9:20 am	Ethical Considerations in the Use of AI in Head and Neck Oncology – Melina Windon, MD				
9:30 am	Practical Uses of AI in Clinical Practice – Janice Farlow – MD, PhD				
9:40 am	Q&A				

9:45 am – 10:15 am Break with Exhibitors

10:15am – 11:00am

Celestin D

**Scientific Session 5: Technology & Education**

Moderators: *Michael Moore, MD, and David Forner, MD, MSc*

**Expert Introduction:** *David Forner, MD, MSc*

1. Virtual Surgical Planning as an Educational and Reconstructive Tool in Head and Neck Outreach: A Collaborative Mission in Uganda – *Alexander Karabachev, MD*
2. Virtual Reality Simulation for Fibula Free Flap Planning among an Otolaryngology-Head and Neck Surgery Resident Cohort – *Hannah L. Kenny, MD*
3. Benchmarking the Competency, Credibility and Consistency of ChatGPT-4o – *Yash V. Shroff, BA*
4. Evaluating the Impact of Multimedia on Patient Comprehension and Decision-Making in Thyroid Surgery: A Randomized Controlled Trial of the Thyroid Informed Surgical Consent Augmenting Video (TISCAV) – *Hani Samarah, BS*
5. Development and Pilot Testing of a High-Fidelity Transoral Robotic Surgery Simulator – *Brett Campbell, MD*

11:00am – 12:00pm

Celestin D

**Panel 7: Enhanced Recovery and Perioperative Protocols for Head and Neck Reconstruction**

Moderators: *Kiran Kakarala, MD and Marianne Abouyared, MD*  
Faculty: *Peter Dziegielewski, MD, FRCSC, Catherine Haring, MD, and Larissa Sweeny, MD*

Head and neck reconstruction comprises complex procedures, often performed on patients with multiple comorbidities, resulting in a high risk of complications and adverse outcomes. This session will explore how enhanced recovery after surgery (ERAS) protocols have the potential to address issues including mental health and substance abuse, malnutrition and medical comorbidities, and operative/post-operative care variation to improve outcomes and optimally support the head and neck cancer patient.

At the conclusion of this session, participants will be able to:

- Identify patients at risk for depression and substance abuse, provide a framework for screening opportunities, and understand available interventions.
- Understand updates in prehabilitation and nutritional recommendations pre-operatively and perioperatively within ERAS protocols.
- Recognize how optimization and standardization of intra-operative and postoperative management can improve outcomes.

11:00 am Introduction to ERAS in Head and Neck Surgery – *Marianne Abouyared, MD*

11:05 am Screening and Intervention for Depression and Substance Abuse – *Larissa Sweeny, MD*

11:20 am Prehabilitation and Nutrition – *Catherine Haring, MD*

11:35 am Evidence Based Intraoperative and Post-Operative Care – *Peter Dziegielewski, MD, FRCSC*

11:50 am Discussion/Q&A

10:15am – 12:00pm

Celestin E

**Jatin Shah Symposium: The Era of Neoadjuvant Immunotherapy for Cutaneous Malignancies is Here (SCC and Melanoma)**

Moderator: *Thomas Ow, MD and Trevor Hackman, MD*

Faculty: *Neil Gross, MD, FACS, Kelly Malloy, MD, Francisco Civantos, MD, Shlomo Koyfman, MD, Carol Lewis, MD, MPH, FACS, Caitlin McMullen, MD, Leslie Fecher, MD*

Dedicated lectures will review the current role for neoadjuvant immunotherapy approaches for cutaneous melanoma and cutaneous squamous cell carcinoma, as well as biomarkers for response. We will provide context and highlight controversies for these approaches using targeted vignettes, discussed by expert panelists.

At the conclusion of this session, participants will be able to:

- Identify patients with cutaneous melanoma and squamous cell carcinoma who would be eligible for neoadjuvant immunotherapy.
- Appraise the current status of predictive biomarkers for response to neoadjuvant immunotherapy for cutaneous melanoma and cutaneous squamous cell carcinoma.
- Formulate appropriate surgical and adjuvant therapeutic plans based on response to neoadjuvant immunotherapy for cutaneous melanoma and cutaneous squamous cell carcinoma.

10:15 am Introduction – Melanoma – *Thomas Ow, MD*

10:17 am Current Status of Neoadjuvant Immunotherapy for Cutaneous Melanoma – *Kelly Malloy, MD*

10:29 am Melanoma – Vignettes – *Francisco Civantos, MD, Leslie Fecher, MD, Kelly Malloy, MD, Carol Lewis, MD, MPH, FACS*

10:39 am Q&A

10:49 am Introduction - Cutaneous Squamous Cell Carcinoma – *Trevor Hackman, MD*

10:51 am Current Status of Neoadjuvant Immunotherapy for Cutaneous Squamous Cell Carcinoma – *Neil Gross, MD, FACS*

11:03 am Cutaneous SCC – Vignettes – *Shlomo Koyfman, MD, Neil Gross, MD, FACS, Caitlin McMullen, MD*

11:13 am Q&A

11:23 am Introduction – Biomarkers – *Thomas Ow, MD*

11:25 am Biomarkers for Response to Neoadjuvant Immunotherapy Approaches for Melanoma and Cutaneous SCC – *Leslie Fecher, MD*

11:37 am Biomarkers – Vignettes – All Panelists

11:47 am Q&A

11:57 am Closing Remarks – *Thomas Ow, MD, Trevor Hackman, MD*

12:00pm – 1:00pm Lunch with Exhibitors



1:00pm – 1:45pm

Celestin D

**Scientific Session 6: Endocrine**

Moderators: *Allen Ho, MD, and Elizabeth Cottrill, MD*

**Expert Introduction:** *Elizabeth Cottrill, MD*

1. Neoadjuvant BRAF/MEK inhibitor therapy and immunotherapy for BRAFV600E-mutated anaplastic thyroid cancers – *Isabelle Fournier, MD, FRCSC*
2. Utilization of Immunotherapy in Anaplastic Thyroid Cancer: Impact on Survival and Disparities in Access – *Josef Madrigal, MD*
3. Association of Socioeconomic, Neighborhood, and Institutional Factors with Presentation in Differentiated Thyroid Cancer: A Population-Based Study of California from 1988 to 2020 – *Nazineen Kandahari, MD, MS*
4. Hypoparathyroidism After Total Thyroidectomy: A Quality of Life Randomized Controlled Trial Comparing Two Treatment Strategies – *Catherine Beaumont, MD, MSc*
5. Is thyroid lobectomy plus neck dissection an effective treatment option in select patients with N1b papillary thyroid carcinoma? – *Daniel W. Scholfield, MD*

1:00pm – 1:45pm

Celestin E

**Panel 8: Innovation and Entrepreneurship Session**

Moderators: *Jose P. Zevallos, MD, MPH, Baran Sumer, MD*  
Faculty: *Alexander Langerman, MD, and Peter Santa Maria, MD*

This session will provide an introduction to entrepreneurship for head and neck surgeon innovators. It will cover the conceptualization of a new idea, the process of disclosing and protecting your intellectual property, putting together a compelling pitch deck, and decision-making around licensing your technology vs. launching a start-up company.

At the conclusion of this session, participants will be able to:

- Broadly discuss the innovation process, from developing and protecting an idea to decision-making around commercialization.
- Discuss the essential elements of creating a compelling pitch deck, and how this differs from a typical scientific presentation.
- Discuss the process of protecting intellectual property and leveraging university resources to support your innovation.

1:00 pm Introduction – *Jose P. Zevallos, MD, MPH*

1:05 pm Understanding the Disclosure and Intellectual Property Process – *Alexander Langerman, MD*

1:15 pm Creating a Compelling Pitch Deck – *Peter Santa Maria, MD*

1:25 pm The Basics of Raising Capital to Support Your Innovation – *Baran Sumer, MD*

1:35 pm Entrepreneurship While Keeping Your Day Job Panel

1:45pm – 2:45pm

Celestin D

**Panel 9: Biomedical and Health Informatics in Head and Neck Mucosal Malignancies**

Moderator: *Clifton Fuller, MD, PhD*

Faculty: *Jennifer Cracchiolo, MD, and Antoine Eskander, MD, ScM, FRCSC*

This panel explores how biomedical and health informatics is transforming the management of head and neck mucosal malignancies. Speakers will define basic concepts in biomedical and clinical informatics and examine cutting-edge approaches—from data integration and predictive analytics to EHR integration—that are reshaping diagnostic and treatment strategies. Join this dynamic discussion to discover how innovative informatics tools are enhancing patient outcomes and streamlining clinical workflows in head and neck oncology.

At the conclusion of this session, participants will be able to:

- Define clinical informatics and denote practical examples of head and neck surgery-relevant ontologies, standards, and nomenclature.
- Identify knowledge gaps and practical improvements to afford greater integration of informatics constructs with clinical and research efforts in mucosal malignancies.
- Identify opportunities and challenges for EHR implementation across use-cases (decision support tool, risk models) to improve patient care.

1:45 pm Not Just the EHR: From Informatics Towards Decision Support – *Clifton Fuller, MD, PhD*

2:02 pm Extending Our Reach: How Remote Monitoring and ePROs Enhance Effective Management – *Jennifer Cracchiolo, MD*

2:19 pm Scaling Quality, Scaling Effectiveness: Health Services Perspectives for Improving Outcomes – *Antoine Eskander, MD, ScM, FRCSC*

2:36 PM Q&A

1:45pm – 2:45pm

Celestin E

**Panel 10: Updates in Management of Advanced and Recurrent Nasopharyngeal Cancer**

Moderator: *Marilene Wang, MD*

Faculty: *Luana Guimaraes De Sousa, MD, Ivan El-Sayed, MD, Meghan Turner, MD, Sue Yom, MD*

This hot topic session will provide an up-to-date review of the role of biomarkers as well ongoing clinical trials including induction chemotherapy, immunotherapy, and vaccine trials in the treatment of nasopharyngeal carcinoma. Novel modalities in chemotherapy, immunotherapy, and radiation therapy will be discussed.

At the conclusion of this session, participants will be able to:

- Integrate the use of biomarkers into nasopharyngeal carcinoma treatment.
- Select patients who may benefit from the addition of induction chemotherapy or immunotherapy in the treatment of nasopharyngeal carcinoma.
- Identify patients who may benefit from novel modalities or de-escalation or reduction in radiotherapy.

1:45 pm Introduction – *Marilene Wang, MD*

1:48 pm The Role of EBV DNA and Liquid Biomarkers in Prognostication and Treatment Selection – *Ivan El-Sayed, MD*

2:00 pm Chemotherapy - Induction vs Concurrent vs Adjuvant: When and Why? – *Luana Guimaraes De Sousa, MD*

2:12 pm Innovations in Radiotherapy (IMRT, proton, AI) – *Sue Yom, MD*

2:24 pm The Evidence for Surgery in the Management of Recurrent NPC – *Meghan Turner, MD*

2:36 pm Q&A

3:15pm - 4:15pm

Celestin D

**Panel 11: Optimizing Form and Function in Benign Parotid Tumor Surgery**Moderator: *David Cognetti, MD*Faculty: *Patrick Tassone, MD, Rusha Patel, MD, and Patrik Pipkorn, MD, MSci*

This session will explore surgical approaches to benign parotid tumors, with an emphasis on optimizing functional and cosmetic outcomes while avoiding tumor recurrence. Incision design, extent of surgery, and reconstructive options will be compared and contrasted.

At the conclusion of this session, participants will be able to:

- Compare incision options for excision of benign parotid tumors.
- Plan optimal extent of resection for benign parotid tumors.
- Identify the appropriate settings for the use of reconstruction for contour defects after benign parotid tumor excision.

3:15 pm Introduction – *David Cognetti, MD*3:25 pm Approaches and Incisions – *Patrick Tassone, MD*3:37 pm Extent of Resection – *Rusha Patel, MD*3:49 pm Contour Reconstruction – *Patrick Pipkorn, MD, MSci*

4:01 pm Cases/Panel Discussion

3:15pm – 4:15pm

Celestin E

**Scientific Session 7: HPV-negative Mucosal Disease**Moderators: *Caitlin McMullin, MD, and Stephen Lai, MD, PhD, FACS***Expert Introduction:** *Caitlin McMullin, MD*

1. Taxane, platinum and cetuximab-based neoadjuvant chemotherapy for patients with locally advanced oral cavity squamous cell carcinoma results in improved survival compared to propensity matched cohort – *Kenric Tam, MD*
2. Machine Learning to Differentiate Mucosal Lesions from Laryngeal Immobility Using Voice Recordings – *Robin Baudouin, MD*
3. A Matched Pair Analysis Comparing Survival in Node Positive Sentinel Node Biopsy and Node Positive Selective Neck Dissection for Oral Cancer. – *Hanan Abu Shamat, MD*
4. Determined at the Margins: Examining the Risk of Dysplastic Margins after Primary Surgery for Oral Cavity SCC – *Jae Gardella, MD*
5. Trends in Initial Management of T4 Laryngeal Squamous Cell Carcinoma – *Annie J. Orr, MD*
6. Circulating tumor DNA (ctDNA) in the Diagnosis and Surveillance of HPV-negative Oral Cavity Carcinoma – *Hannah Q. Baratz, BS*
7. Distinct bacterial signatures and metagenomic alterations associated with lymph node metastasis in laryngeal cancer – *Natalie Silver, MD*

4:15pm - 5:15pm

Celestin D

**Panel 12: Survivorship in Sinonasal and Nasopharyngeal Cancers**Moderator: *Shirley Su, MBBS*Faculty: *Rahul Mehta, MD, Zara Patel, MD, Oded Sagiv, MD, and Robert Ferguson, MD*

This session will describe survivorship issues in head and neck skull base tumors, including endocrine, neurocognitive, vestibular-auditory and ophthalmic sequelae of surgery and multimodality management for skull base tumors. We will discuss patterns of neurocognitive decline related to chemotherapy, systemic therapy, radiotherapy and surgery, diagnosis and treatment. We will highlight the impact of surgery, radiotherapy, and systemic therapy on the orbit and vestibulo-auditory as well as an overview of treatment options. Impact of treatment on the endocrine system and recommendations for screening, as well as the impact of loss of smell and nutrition on long term survival and function will be described.

At the conclusion of this session, participants will be able to:

- Understand the effects of cancer and treatment on the CNS and strategies to cope with change.
- Evaluate the effects of head and neck cancer therapies on the olfactory, endocrine and vestibulo-auditory system.
- Describe the effects of cancer and therapies on the orbit and management strategies.

4:15pm - 5:15pm

Celestin E

**Reconstruction Debates: Can AI Do It All?**Moderator: *Matthew Old, MD, and Rodrigo Bayon, MD*Faculty: *Andres Bur, MD, Joel Davies, MD, MSc, and Nolan Seim, MD*

We will use a debate style format to emphasize the impact artificial intelligence (AI) is having on the field of head and neck reconstruction. We will discuss current and future uses as well as limitations of the technology.

At the conclusion of this session, participants will be able to:

- Identify pros and cons of artificial intelligence in head and neck reconstruction.
- Discuss current limitations of AI in head and neck reconstruction.
- Recognize future applications of AI within the field of head and neck reconstruction.

4:15 pm Introduction – *Matthew Old, MD*4:18 pm Emerging Role of AI in Head and Neck Reconstruction – *Rodrigo Bayon, MD*4:23 pm Debate: Should AI-Guided Resection Planning Take Precedence Over Surgeon Discretion? – *Andres Bur, MD*4:30 PM Debate: Should AI-Guided Resection Planning Take Precedence Over Surgeon Discretion? – *Nolan Seim, MD*4:37 pm Debate: Can AI Improve Outcomes in Microsurgical Free Flap Reconstruction? – *Joel Davies, MD, MSc*4:44 pm Debate: Can AI Improve Outcomes in Microsurgical Free Flap Reconstruction? – *Andres Bur, MD*4:55 PM Debate: Will AI-Optimized Prosthetics Surpass Traditional Customization? – *Nolan Seim, MD*5:02 PM Debate: Will AI-Optimized Prosthetics Surpass Traditional Customization? – *Joel Davies, MD, MSc*

5:09 PM Q&amp;A

4:15 pm Introduction – *Shirley Su, MBBS*  
4:20 PM Olfaction After Multimodality Therapy: Impact on Patient, Nutrition, Assessment, and Intervention – *Zara Patel, MD*  
4:30 PM The Effects of Cancer Multimodality Therapy on the Vestibular-Auditory Systems – *Rahul Mehta, MD*  
4:40 PM Neurocognitive Impairment in Head and Neck Cancer Survivorship – *Robert Ferguson, MD*  
4:50 PM Orbital Function – Understanding Radiotherapy and Systemic Therapy Sequelae and Interventions – *Oded Sagiv, MD*  
5:00 PM Q&A

Time	Title	Location
<b>5:30pm - 7:00pm</b>	<b>Poster Session/Reception COSM “Meet the Authors” Poster Tours</b>	<b>Elite Hall</b>

<b>7:00pm - 8:00pm</b>	<b>President’s Reception</b>	<b>Strand 11A</b>
Please join AHNS President, Dr. William Lydiatt, for complimentary drinks and appetizers. This is open to all AHNS attendees.		